MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

41.06 2.93

Overview

Share price change

24h

Current

Min

39.77

Max

41.71

Key metrics

By Trading Economics

Income

-48M

-27M

Sales

3M

99M

Profit margin

-27.41

Employees

979

EBITDA

3.2M

-21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+8.44% upside

Dividends

By Dow Jones

Next Earnings

2 lut 2026

Market Stats

By TradingEconomics

Market Cap

462M

2.3B

Previous open

38.13

Previous close

41.06

News Sentiment

By Acuity

50%

50%

151 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sty 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 sty 2026, 00:00 UTC

Earnings

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 sty 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 sty 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 sty 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 sty 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 sty 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 sty 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 sty 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 sty 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 sty 2026, 22:09 UTC

Earnings

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 sty 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Announces Positive Profit Alert for 2025

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Citigroup Acting as Financial Advisor to WuXi XDC

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 sty 2026, 21:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

14 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 sty 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Makes Cash Offer for BioDlink International

14 sty 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 sty 2026, 20:30 UTC

Market Talk
Earnings

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 sty 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 sty 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 sty 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 sty 2026, 19:06 UTC

Market Talk
Earnings

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

8.44% upside

12 Months Forecast

Average 41.25 USD  8.44%

High 43 USD

Low 39 USD

Based on 5 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

151 / 361 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat